CD19 and neoplasm: This finding is in contrast to that described for an anti-CD19 IgG-scTRAIL heterodimeric fusion protein containing one scTRAIL moiety, for which potent killing of CD19-positive tumor cells was observed in vitro and in vivo, whereas a control fusion protein targeting HER2 was inefficient29.